Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS?

https://doi.org/10.20996/1819-6446-2013-9-6-682-689

Full Text:

Abstract

The review presents recent data on the usage of platelet functional tests in patients with ischemic heart disease after percutaneous coronary intervention and its contribution to antiplatelet therapy personalization and cardiovascular events frequency reduction.

About the Authors

Yu. I. Grinshtein
Krasnoyarsk State Medical University named after Prof. Voyno-Yasenetsky, Krasnoyarsk
Russian Federation


A. A. Kosinova
Krasnoyarsk State Medical University named after Prof. Voyno-Yasenetsky, Krasnoyarsk
Russian Federation


I. Yu. Grinshtein
Krasnoyarsk State Medical University named after Prof. Voyno-Yasenetsky, Krasnoyarsk
Russian Federation


References

1. Kushner F.G., Hand M., Smith S.C.Jr., et al. Review 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol 2009;54(23):2205-41.

2. Wenaweser P., Daemen J., Zwahlen M., et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52(14):1134-40.

3. Dangas G.D., Caixeta A., Mehran R., et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011;123(16):1745-56.

4. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303(8):754-62.

5. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369(9562):667-78.

6. vanWerkum J.W., Heestermans A.A., de Korte F.I., et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis. An analysis of 431 cases. Circulation 2009;119(6):828-34.

7. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293(17):2126-30.

8. de la Torre Hernndez J.M., Alfonso F., Gimeno F., et al. Thrombosis of second-generation drug-eluting stents in real practice: results from the multicenter Spanish registry ESTROFA-2 (estudioespaolso- bretrombosis de stents farmacoactivos de segunda generacion-2). JACC: Cardiovascular Interventions 2010; 3(9):911-19.

9. Lemesle G., Sudre A., Modine T., et al. High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. Catheterization and Cardiovascular Interventions 2008;72(4):470-78.

10. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116(7):745-54.

11. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48(1): 193-202.

12. Aradi D., Komócsi A., Vorobcsuk A., et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160(3):543-51.

13. Campo G., Fileti L., Valgimigli M., et al. Poor response to clopidogrel: current and future options for its management. J Thromb and Thrombolysis 2010;30(3):319-31.

14. Elsenberg E.H., van Werkum J.W., van de Wal R.M., et al. The influence of clinical characteristics, laboratory and inflammatory markers on “high on-treatment platelet reactivity” as measured with different platelet function tests. Thromb Haemost 2009;102(4):719-27.

15. Gori A.M., Marcucci R., Paniccia R., et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008;100(6):1136-45.

16. Collet J.P., Cuisset T., Rangé G., et al. Bedside monitoring to adjust antiplatelet therapy for coronarystenting. N Engl J Med 2012;367(22): 2100-09.

17. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am CollCardiol 2006;48(9):1742-50.

18. Greenstein YuI, Filonenko IV, Savchenko AA, et al. Patent № 2413953 Russian Federation: MPKG01N 33/86. The method of acetylsalicylic acid resistance diagnosing. Krasnoyarsk State Medical University named after Professor V.F.Voyno-Yasenetsky. № 2009131242/15, publ. 10.03.2011;(7):8. Russian (Гринштейн Ю.И., Филоненко И.В., Савченко А.А., и др. Патент №2413953 РФ: МПКG01N 33/86. Способ диагностики резистентности к ацетилсалициловой кислоте. Красноярский государственный медицинский университет им. профессора В.Ф.Войно-Ясенецкого. №2009131242/15; опубликовано 10.03.2011; (7):8.

19. Paniccia R., Antonucci E., Gori A.M., et al.Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5(9):1839-47.

20. Lordkipanidzé M., Pharand Ch., Schampaert E., et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-08.

21. Аleil B., Ravanat C., Cazenave J.P., et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3(1):85-92.

22. Kulkarni S., Dopheide S.M., Yap C.L., et al. A revised model of platelet aggregation. J Clin Invest 2000;105(6):783-91.

23. Geiger J., Teichmann L., Grossmann R.,et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005;51(6):957-65.

24. Favaloro E.J. Clinical application of the PFA-100. Curr Opin in Hematol 2002;9(5):407-15.

25. Sibbing D., Morath T., Braun S., et al. Clopidogrel response status assessed with Multiplate point-ofcare analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010;103(1):151-9.

26. Sibbing D., Braun S., Jawansky S., et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008;99(1):121-6.

27. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46(10):1820-6.

28. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1(8):1710-3.

29. Ohmori T., Yatomi Y., Nonaka T., et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006;4(6):1271-8.

30. Catella F., Fitzgerald G.A. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987;47(6):647-56.

31. Gonzalez-Conejero R., Rivera J., Corral J., et al. Biological Assessment of Aspirin Efficacy on Healthy Individuals: Heterogeneous Response or Aspirin Failure? Stroke 2005;36:276-80.

32. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303(8):754-62.

33. Bonello L., Tantry U. S., Marcucci R., at al. Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. JACC 2010;56(12):919-33.

34. Frere C., Cuisset T., Quilici J., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98:838-43.

35. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator- stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. A multicenter randomized prospective study. J Am Coll Cardiol 2008;51(14):1404-11.

36. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10.

37. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000.

38. Valgimigli M., Campo G., de Cesare N., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-22.

39. Patti G., Nusca A., Mangiacapra F., et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-33.

40. Gurbel P.A., Antonino M.J., Bliden K.P., et al. Platelet reactivity to adenosinediphosphate and longterm ischemic event occurrencefollowing percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008;19:595-604.

41. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with pointof-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53(10):849-56.

42. Geisler T., Zürn C., Simonenko R., et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010;31(1):59-66.

43. Palmerini T., Coller B.S., Cervi V., et al. Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. J Am Coll Cardiol 2004;44:1570-77.

44. Cheneau E., Leborgne L., Mintz G.S., et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003;108:43-7.

45. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49(24):2312-17.

46. Lev E.I., Alviar C.L., Arikan M.E., et al. Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. American Heart J 2007;153(1):e1-6.

47. Funck-Jensen K.L., Dalsgaard J., Grove E.L., et al. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets 2013;24(7):528-37.

48. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306(11):1215-23.

49. Brar S.S., ten Berg J., Marcucci R., et al. Impact of platelet reactivity on clinical outcomes after per- cutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-54.

50. Eshtehardi P., Windecker S., Cook S., et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010;159(5):891-8.

51. Gori A.M., Marcucci R., Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52(9):734-9.

52. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay a 12-month follow-up. Circulation 2009;119(2):237-42.

53. Gremmel T., Steiner S., Seidinger D., et al. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 2011;128(4):352-7.

54. Michelson A.D., Frelinger III A. L., Braunwald E., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753-63.

55. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.

56. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.

57. Trenk D., Stone G.W., Gawaz M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159-64.

58. Price M.J., Angiolillo D.J., Teirstein P.S., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132-7.

59. Siller-Matula J.M., Francesconi M., Dechant C., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013;167(5):2018-23.

60. Aradi D., Komócsi A., Price M.J., et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol 2013;167(5):2140-48.

61. Gurbel P.A., Tantry U.S. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. The Journal of the American Medical Association 2011;305(11):1136-7.


For citation:


Grinshtein Yu.I., Kosinova A.A., Grinshtein I.Yu. ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? Rational Pharmacotherapy in Cardiology. 2013;9(6):682-689. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-6-682-689

Views: 489


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)